BioCentury | Dec 3, 2007
Strategy

Astellas' biologics cornerstone

...which has 30 targets in 14 cancer types. The company was founded in 1996 as UroGenesys Inc....
BioCentury | Mar 11, 2002
Finance

Ebb & Flow

...a 2001 deal with Biosearch Italia (NMerc:BIO). Private rounds Monoclonal cancer drug developer Agensys (formerly UroGenesys...
BioCentury | Mar 5, 2002
Financial News

Agensys raises $42.8 million

...Lombard Odier; and other investors. JPMorgan acted as placement agent and advisor. Agensys (formerly UroGenesys...
BioCentury | May 14, 2001
Company News

UroGenesys management update

UroGenesys Inc., Santa Monica, Calif. Business: Cancer Promoted: Aya Jakobovits to SVP of technology and corporate development from VP of research, while remaining CSO Hired: Paul Kanan as VP of operations and CFO, formerly president...
BioCentury | Mar 5, 2001
Clinical News

UroGenesys preclinical data

...Researchers with Urogenesys published in the Proceedings of the National Academy of Sciences that 1G8 and...
...in treated mice. Both MAbs are partnered with Genentech Inc. (DNA, South San Francisco, Calif.). Urogenesys Inc....
BioCentury | Feb 12, 2001
Company News

MorphoSys management update

...and Mary Anderson as senior director of corporate development, formerly director of business development at UroGenesys Inc. WIR...
BioCentury | Oct 30, 2000
Company News

Amgen board of directors update

...Amgen Inc. (AMGN), Thousand Oaks, Calif. Business: Biopharmaceuticals Appointed: Donald Rice, president and CEO of UroGenesys Inc. WIR...
BioCentury | Jul 24, 2000
Company News

Genentech, UroGenesys deal

...DNA acquired exclusive worldwide rights to develop antibody based cancer therapeutics against UroGenesys' Prostate Stem Cell...
...DNA also received rights to a panel of monoclonal antibodies in preclinical development against PCSA. UroGenesys...
...million in milestones and other payments, plus royalties. Genentech Inc. (DNA), South San Francisco, Calif. UroGenesys Inc....
BioCentury | Jul 18, 2000
Company News

UroGenesys licenses antigen to Genentech

...DNA acquired exclusive worldwide rights to develop antibody based therapeutics to treat cancer using UroGenesys' Prostate...
...as a target. DNA also received rights to a panel of monoclonal antibodies against PCSA. UroGenesys...
BioCentury | Mar 6, 2000
Company News

UroGenesys, Protein Pathways deal

...bioinformatics technology to UroGenesys' database of cancer-associated antigens to identify potential targets for cancer therapies. UroGenesys Inc....
Items per page:
1 - 10 of 20
BioCentury | Dec 3, 2007
Strategy

Astellas' biologics cornerstone

...which has 30 targets in 14 cancer types. The company was founded in 1996 as UroGenesys Inc....
BioCentury | Mar 11, 2002
Finance

Ebb & Flow

...a 2001 deal with Biosearch Italia (NMerc:BIO). Private rounds Monoclonal cancer drug developer Agensys (formerly UroGenesys...
BioCentury | Mar 5, 2002
Financial News

Agensys raises $42.8 million

...Lombard Odier; and other investors. JPMorgan acted as placement agent and advisor. Agensys (formerly UroGenesys...
BioCentury | May 14, 2001
Company News

UroGenesys management update

UroGenesys Inc., Santa Monica, Calif. Business: Cancer Promoted: Aya Jakobovits to SVP of technology and corporate development from VP of research, while remaining CSO Hired: Paul Kanan as VP of operations and CFO, formerly president...
BioCentury | Mar 5, 2001
Clinical News

UroGenesys preclinical data

...Researchers with Urogenesys published in the Proceedings of the National Academy of Sciences that 1G8 and...
...in treated mice. Both MAbs are partnered with Genentech Inc. (DNA, South San Francisco, Calif.). Urogenesys Inc....
BioCentury | Feb 12, 2001
Company News

MorphoSys management update

...and Mary Anderson as senior director of corporate development, formerly director of business development at UroGenesys Inc. WIR...
BioCentury | Oct 30, 2000
Company News

Amgen board of directors update

...Amgen Inc. (AMGN), Thousand Oaks, Calif. Business: Biopharmaceuticals Appointed: Donald Rice, president and CEO of UroGenesys Inc. WIR...
BioCentury | Jul 24, 2000
Company News

Genentech, UroGenesys deal

...DNA acquired exclusive worldwide rights to develop antibody based cancer therapeutics against UroGenesys' Prostate Stem Cell...
...DNA also received rights to a panel of monoclonal antibodies in preclinical development against PCSA. UroGenesys...
...million in milestones and other payments, plus royalties. Genentech Inc. (DNA), South San Francisco, Calif. UroGenesys Inc....
BioCentury | Jul 18, 2000
Company News

UroGenesys licenses antigen to Genentech

...DNA acquired exclusive worldwide rights to develop antibody based therapeutics to treat cancer using UroGenesys' Prostate...
...as a target. DNA also received rights to a panel of monoclonal antibodies against PCSA. UroGenesys...
BioCentury | Mar 6, 2000
Company News

UroGenesys, Protein Pathways deal

...bioinformatics technology to UroGenesys' database of cancer-associated antigens to identify potential targets for cancer therapies. UroGenesys Inc....
Items per page:
1 - 10 of 20